Bio-Technopark
In very close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital, a science park for life science companies and institutions has developed in the last two decades, which has now acquired both national and international significance. On the former site of the Schweizerische Wagons- und Aufzügefabrik AG and on neighboring sites, 90,000 m2 of laboratory, production and office space is now leased to over 50 companies and 30 academic institutions.
Leasing
In the Bio-Technopark, it is possible to rent ultramodern laboratories, offices, and complex infrastructure for research and development purposes. The premises offered include fully-equipped laboratory facilities with communal infrastructure, and individual rental areas in different sizes and locations and with different fit-out standards. The Bio-Technopark is still being developed and gradually fitted out.
Services
The Bio-Technopark promotes the transfer of knowledge and technology, as well as the foundation and building up of life science companies. In addition to advice, coaching, and support for those who are setting up and developing companies and looking for financing, its services include the organization of events that focus on networking, facilitating the exchange of ideas between specialists, and advanced training.
News
Initiation of a Phase 3 Study of ALXN2220 for the Treatment of Transthyretin-mediated Amyloid Cardiomyopathy
Zurich, Switzerland - 04.04.2024 Neurimmune today announced that its collaboration partner Alexion, AstraZeneca’s Rare Disease group, initiated the Phase 3 DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 (formerly NI006) for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) (NCT06183931). ALXN2220 is an investigational human monoclonal antibody designed to deplete...
Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research
ZURICH, Switzerland and FREMONT, California, US April 4, 2024 (GlobeNewswire). Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid...